Discover Grünenthal


Aachen / Santiago de Chile, December 27, 2013. The Grünenthal Group today announced the acceptance of the public tender offer with respect to the acquisition of all issued and outstanding shares of Laboratorios Andrómaco S.A. Inversiones Gruchi Limitada, a subsidiary of Grünenthal GmbH, Germany, has acquired 81.59% of all issued and outstanding shares of Laboratorios Andrómaco S.A. through a public tender offer. The offer period ended on December 24, 2013. Shareholders of Laboratorios Andrómaco S.A. who tendered their shares receive CLP 332.48 per share in cash.


Aachen, Germany / Redwood City (California), USA – December 16, 2013 – Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self-administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, EEA and Australia. AcelRx will supply Grünenthal with the product and retains all rights in remaining countries including the US and Asia.


Aachen / Santiago de Chile, November 25, 2013. Inversiones Gruchi S.A., a subsidiary of Grünenthal GmbH Germany yesterday published its public tender offer for the purchase of all outstanding shares in Laboratorios Andrómaco S.A. (Securities Registry No. 704). Grünenthal offers CLP 332.48 per share in cash. The offer price represents a premium of 66.99% on the closing price of Sept 6, the last trading day before the disclosure of the agreement between major Laboratorios Andrómaco S.A. shareholders and Grünenthal.


Aachen, October 28, 2013 – 96 million Europeans suffer from chronic pain.1,2 21% of these people have been affected for more than 20 years. Across Europe chronic pain accounts for nearly 500 million lost working days per year – costing the European economy around € 34 billion.1 However, the average period between initial symptoms of chronic pain disease and the beginning of adequate therapeutic intervention is four years, as shown by a recent study in Germany.3


Aachen, Germany, October 12, 2013. Today´s third International Day Against Pain is designed to give a voice to people suffering from pain, to provide information about the treatments that are available, to create a global alliance to broadcast the right to treatment and to raise funds for scientific research.


Florence, October 11th, 2013. – Worldwide millions of patients are tortured by a pain that is unexplainable for them. In a series of Meet-the-expert sessions hosted by Grünenthal at the 8th EFIC Pain in Europe congress in Florence, Italy, experts explained that in approximately 60% of cases, neuropathic pain is localized affecting a specific circumscribed area of the body.


Florence, October 10th 2013. As the field of pain has evolved significantly in Europe over the years, pain research is more relevant than ever: Every fifth adult citizen in Europe suffers from persistent or chronic pain, so pain has become a major health problem in Europe. In line with the thought that pain research is getting more and more important, the EFIC-Grünenthal Grant (E-G-G) gave young scientists support and a platform in the course of the 8th EFIC® Congress in Florence, Italy.


Aachen (Germany)/Santiago de Chile (Chile), September 9, 2013. Grünenthal, the international research-based pharmaceutical company headquartered in Aachen, Germany, has reached certain agreements with two major shareholders of Laboratorios Andrómaco S.A to enter into an in-depth due diligence process of the company. Following a successful completion of this due diligence, Grünenthal intends to launch a public tender offer for all outstanding shares of Laboratorios Andrómaco S.A. later this year followed by an effective closing of the transaction until end of 2013. Sergio Weinstein as one of the major shareholders intends to keep a significant stake in the company and remain as minority shareholder.



Aachen, September 9th 2013. The shareholders of the Grünenthal Group have assigned Dr. Wilhelm Moll, LL.M. (63) member of the supervisory board of the international pharmaceutical company headquartered in Aachen. In a meeting on September 6th, Dr. Moll was additionally elected chairman of the supervisory board. As of October 12th 2013 he will as well take over the responsibility of chairman of the advisory board of the Grünenthal Group. Furthermore, with effect from October 12th 2013 Edouard Croufer (66) has been elected member of the advisory board of Grünenthal Pharma GmbH & Co. KG and Grünenthal GmbH.

Florian Dieckmann Head Global Communication

Florian Dieckmann

Head Global Communication

Grünenthal GmbH

52099 Aachen


Fabia Kehren, Head External Communications and Editorial Management

Fabia Kehren

Head of External Communication

Grünenthal GmbH

52099 Aachen

Phone +49 241 569-3269